The first drug of its kind was just approved, and it could signal a massive change for pharmaceuticals
Advertisement
Thomson Reuters
Advertisement
The drug contains the same active ingredient as Neupogen, or filgrastim, which logged 2014 worldwide sales of $1.2 billion for manufacturer Amgen.
The Food and Drug Administration (FDA) said it approved Zarxio for treating the same five conditions for which Neupogen is used.
The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.
Advertisement
(Reporting by Ben Hirschler. Editing by Jane Merriman)
Advertisement
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Catan adds climate change to the latest edition of the world-famous board game
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- JNK India IPO allotment – How to check allotment, GMP, listing date and more
- Indian Army unveils selfie point at Hombotingla Pass ahead of 25th anniversary of Kargil Vijay Diwas